Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.

Wu X, Zhou T, O'Dell S, Wyatt RT, Kwong PD, Mascola JR.

J Virol. 2009 Nov;83(21):10892-907. doi: 10.1128/JVI.01142-09. Epub 2009 Aug 19.

2.
3.

Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.

Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Ledgerwood JE, Graham BS, Haynes BF, Burton DR, Wyatt RT, Mascola JR.

J Virol. 2011 Sep;85(17):8954-67. doi: 10.1128/JVI.00754-11. Epub 2011 Jun 29.

5.

Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.

Wu L, Zhou T, Yang ZY, Svehla K, O'Dell S, Louder MK, Xu L, Mascola JR, Burton DR, Hoxie JA, Doms RW, Kwong PD, Nabel GJ.

J Virol. 2009 May;83(10):5077-86. doi: 10.1128/JVI.02600-08. Epub 2009 Mar 4.

7.

Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.

Nakamura GR, Byrn R, Wilkes DM, Fox JA, Hobbs MR, Hastings R, Wessling HC, Norcross MA, Fendly BM, Berman PW.

J Virol. 1993 Oct;67(10):6179-91.

8.
9.

Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.

Zhang MY, Xiao X, Sidorov IA, Choudhry V, Cham F, Zhang PF, Bouma P, Zwick M, Choudhary A, Montefiori DC, Broder CC, Burton DR, Quinnan GV Jr, Dimitrov DS.

J Virol. 2004 Sep;78(17):9233-42.

10.
11.

Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.

Utachee P, Nakamura S, Isarangkura-Na-Ayuthaya P, Tokunaga K, Sawanpanyalert P, Ikuta K, Auwanit W, Kameoka M.

J Virol. 2010 May;84(9):4311-20. doi: 10.1128/JVI.02619-09. Epub 2010 Feb 17.

12.

Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.

Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C, Wang L, Hendrickson WA, Sodroski J, Wyatt R.

Virology. 2003 Sep 1;313(2):387-400.

13.

Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.

Wyatt R, Thali M, Tilley S, Pinter A, Posner M, Ho D, Robinson J, Sodroski J.

J Virol. 1992 Dec;66(12):6997-7004.

14.

Structural definition of a conserved neutralization epitope on HIV-1 gp120.

Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD.

Nature. 2007 Feb 15;445(7129):732-7.

15.

The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.

Pugach P, Kuhmann SE, Taylor J, Marozsan AJ, Snyder A, Ketas T, Wolinsky SM, Korber BT, Moore JP.

Virology. 2004 Mar 30;321(1):8-22.

16.

Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.

Ingale J, Tran K, Kong L, Dey B, McKee K, Schief W, Kwong PD, Mascola JR, Wyatt RT.

J Virol. 2014 Dec;88(24):14002-16. doi: 10.1128/JVI.02614-14. Epub 2014 Sep 24. Erratum in: J Virol. 2015 Jun;89(12):6526.

17.

Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12.

Pantophlet R, Wilson IA, Burton DR.

Protein Eng Des Sel. 2004 Oct;17(10):749-58. Epub 2004 Nov 12.

PMID:
15542540
18.

Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.

Sterjovski J, Churchill MJ, Ellett A, Wesselingh SL, Ramsland PA, Gorry PR.

Virology. 2012 Oct 25;432(2):394-404. doi: 10.1016/j.virol.2012.06.024. Epub 2012 Jul 19.

19.

Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.

Prabakaran P, Gan J, Wu YQ, Zhang MY, Dimitrov DS, Ji X.

J Mol Biol. 2006 Mar 17;357(1):82-99. Epub 2006 Jan 9.

PMID:
16426633
20.

A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.

Gach JS, Quendler H, Tong T, Narayan KM, Du SX, Whalen RG, Binley JM, Forthal DN, Poignard P, Zwick MB.

PLoS One. 2013 Aug 26;8(8):e72054. doi: 10.1371/journal.pone.0072054. eCollection 2013.

Supplemental Content

Support Center